Search
Search
#1. 《氣喘》Tezepelumab 的III 期臨床試驗SOURCE 之結果
說明: * Tezepelumab 是一種胸腺基質淋巴生成素(thymic stromal lymphopoietin, TSLP) 抑制劑,TSLP 是一種上皮細胞細胞因子,作用 ...
#2. Tezepelumab in Adults and Adolescents with Severe ...
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in the ...
#3. 氣喘個人化醫療新時代!首支廣泛嚴重氣喘群體的生物製劑藥物 ...
美國食品藥物管理局(FDA)近期核准阿斯特捷利康(AstraZeneca, AZ)與安進(Amgen)共同開發的藥物Tezspire(tezepelumab-ekko)用於治療嚴重氣喘, ...
Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma. ... It blocks thymic stromal lymphopoietin (TSLP) ...
#5. Tezspire (tezepelumab) approved in the US for ... - AstraZeneca
2021年12月17日 — Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal ...
#6. FDA APPROVES TEZSPIRE™ (TEZEPELUMAB ... - Amgen
2021年12月17日 — Tezspire is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the ...
#7. Effect of tezepelumab on airway inflammatory cells ... - PubMed
由 S Diver 著作 · 2021 · 被引用 7 次 — Background: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial cell- ...
試驗計畫標題(名稱), 一項多中心、隨機分配、雙盲、安慰劑對照、平行分組之第三期試驗,評估Tezepelumab用於嚴重氣喘控制不佳成人與青少年患者的療效與安全性.
#9. Reference ID: 4907025 - Accessdata.fda.gov
TEZSPIRE™ (tezepelumab-ekko) injection, for subcutaneous use. Initial U.S. Approval: 2021 ... Known hypersensitivity to tezepelumab-ekko or excipients. (4).
#10. FDA Approves Tezepelumab for Severe Asthma - American ...
The FDA Friday approved tezepelumab, the first biologic that targets thymic stromal lymphopoietin (TSLP), for severe asthma.
#11. Tezepelumab - an overview | ScienceDirect Topics
Tezepelumab is a human monoclonal antibody that binds to TSLP, an epithelium-derived alarmin that is heavily implicated in the pathogenesis of asthma [99–101].
#12. Study to Evaluate Tezepelumab in Adults & Adolescents With ...
Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. The study also ...
#13. Mechanism of action by which tezepelumab improves clinical ...
Background: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis, from ...
#14. FDA Approves Tezepelumab-ekko (Tezspire) for Severe Asthma
Tezepelumab -ekko is a human monoclonal antibody that acts as a thymic stromal lymphopoietin (TSLP) blocker. TSLP is an epithelial-cell–derived ...
#15. Effect of tezepelumab on airway inflammatory cells ...
Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP), an epithelial cell-derived ...
#16. Effect of Tezepelumab on Exacerbations in Patients with ...
Tezepelumab is a human monoclonal antibody that blocks activity of thymic stromal lymphopoietin (TSLP), an epithelial cytokine implicated in asthma ...
#17. Efficacy of tezepelumab in patients with low and high ...
Background: In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced annualized asthma exacerbation rates (AAER) by up to 71% versus placebo in adults ...
#18. FDA approves tezepelumab for severe asthma - Healio
Tezepelumab (Tezspire, Amgen/AstraZeneca) is a first-in-class biologic for severe asthma that aids in stopping inflammation that causes asthma ...
#19. New Phase III Data Reaffirms Tezepelumab's Potential for ...
Tezepelumab, an injectable subcutaneous monoclonal antibody, is one of the more advanced monoclonal antibodies that blocks TSLP. Recent clinical ...
#20. ICER Publishes Evidence Report on Tezepelumab for Severe ...
Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab ...
#21. Tezepelumab as an Emerging Therapeutic Option for the ...
Tezepelumab is the first investigational monoclonal antibody that inhibits human thymic stromal lymphopoietin receptor. It has been described as ...
#22. Tezepelumab in... - The New England Journal of Medicine
Tezepelumab in Patients with Severe, Uncontrolled Asthma - Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin, ...
#23. Tezepelumab for treating severe asthma [ID3910] - NICE
Suggested remit: To appraise the clinical and cost effectiveness of tezepelumab within its marketing authorisation for treating severe asthma.
#24. a025 tezepelumab efficacy in severe asthma by specific ...
Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin. In the PATHWAY phase 2b study (NCT02054130), ...
#25. tezepelumab | Ligand page - IUPHAR/BPS Guide to ...
Comment: Tezepelumab is a fully human IgG2λ monoclonal antibody, that is a potential first-in-class agent that blocks the epithelial-cell-derived cytokine ...
#26. Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults ...
D7. D007 ADVANCES IN ASTHMA THERAPIES · Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults with Severe Asthma.
#27. Tezepelumab Effective in Patients With Severe Uncontrolled ...
An exploratory analysis from phase 3 of the NAVIGATOR trial found that tezepelumab reduced exacerbations and improved lung function and ...
#28. FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN ...
Tezspire is a first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the ...
#29. DESTINATION - Respiratory Research
Background. Tezepelumab is a human monoclonal antibody that blocks the activity of the epithelial cytokine thymic stromal lymphopoietin.
#30. Tezspire (tezepelumab-ekko) FDA Approval History - Drugs.com
FDA approval history for Tezspire (tezepelumab-ekko) used to treat Asthma. Supplied by Amgen and AstraZeneca.
#31. Tezepelumab Granted Orphan Drug Status for Eosinophilic ...
Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin, ...
#32. ICER says Amgen's tezepelumab 'likely to be too expensive' -
The FDA granted breakthrough therapy designation to tezepelumab for the treatment of patients with severe non-eosinophilic asthma, and an FDA ...
#33. TEZSPIRE (tezepelumab) Approved in the ... - Yahoo Finance
TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma · First and only biologic to consistently and significantly reduce exacerbations in a ...
#34. Amgen、AZ氣喘新藥臨床三期未達終點挑戰口服類固醇療法失敗
11月時,安進(Amgen)、阿斯特捷利康(AstraZeneca)表示,其共同開發的市場首見(first-in-class)氣喘新藥tezepelumab,在臨床三期試驗NAVIGATOR中達到 ...
#35. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled ...
Conclusions. Treatment with tezepelumab reduced exacerbations, improved lung function, and reduced type 2 biomarkers versus placebo in patients ...
#36. AZ/Amgen Fail In EU Fast-Track Bid For Tezepelumab - Pink ...
European drug reviewers are not convinced that AstraZeneca and Amgen's investigational treatment for severe asthma, tezepelumab, ...
#37. AstraZeneca drops Dupixent rival tezepelumab in atopic ...
While tezepelumab has failed in atopic dermatitis, it has delivered better results in other indications, most notably asthma. The FDA granted ...
#38. Tezepelumab regulatory submission accepted and granted ...
Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma.
#39. Tezepelumab: Uses, Interactions, Mechanism of Action
Tezepelumab is a human monoclonal IgG2λ thymic stromal lymphopoietin (TSLP)-blocking antibody for add-on maintenance therapy in severe ...
#40. FDA Grants AstraZeneca's Tezepelumab Orphan Drug ...
According to a company press release, tezepelumab is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP), a ...
#41. AstraZeneca stands up to respiratory rivals with tezepelumab ...
On Friday, the FDA bestowed its breakthrough therapy designation on candidate tezepelumab, a severe asthma drug that treats a broader ...
#42. Tezepelumab in Adults and Adolescents with Severe ...
BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in the ...
#43. Tezepelumab reduces serious exacerbations in severe asthma
Tezepelumab, codeveloped by Amgen and AstraZeneca, has a novel mechanism of action. It blocks thymic stromal lymphopoietin (TSLP), which is a ...
#44. Tezepelumab Data Continue to Show Promise for a Broad ...
Blood eosinophil counts and FeNO levels are 2 key inflammatory biomarkers used by clinicians to inform treatment options and were defined as ...
#45. FDA grants priority review for AZ, Amgen's tezepelumab for ...
The companies' FDA submission for tezepelumab for the treatment of severe asthma patients is based on results from the PATHFINDER clinical ...
#46. Tezepelumab: A Potential New Biological Therapy for Severe ...
Tezepelumab is a fully human monoclonal antibody that binds to TSLP, ... of randomized clinical trials suggest that tezepelumab is characterized by a good ...
#47. AstraZeneca and Amgen receive breakthrough status for ...
AstraZeneca and Amgen have received breakthrough therapy designation for tezepelumab drug to treat severe asthma, irrespective of an ...
#48. Tezepelumab normalizes serum interleukin-5 and -13 levels ...
Tezepelumab is an anti-TSLP human monoclonal antibody. In the PATHWAY phase 2b (NCT02054130) and NAVIGATOR phase 3 (NCT03347279) studies, ...
#49. Tezepelumab Biosimilar – Anti-TSLP mAb – Research Grade
Buy Tezepelumab Biosimilar - Anti-TSLP mAb - Research Grade Online. Shop among our wide range of biosimilars available at highly competitive prices.
#50. ICER releases revised evidence report on tezepelumab for ...
Key clinical findings. For the treatment of severe uncontrolled asthma, the evidence provides high certainty that tezepelumab is at least ...
#51. ICER Foresees AstraZeneca's Tezepelumab for Severe ...
Tezepelumab is a potential first-in-class therapy for severe asthma. It is a monoclonal antibody that inhibits the action of TSLP, an epithelial ...
#52. After flunking one study, Amgen's tezepelumab shows ...
Amgen has announced that the experimental monoclonal antibody tezepelumab demonstrated a meaningful reduction in asthma symptoms.
#53. Advancing in Asthma - Pharmaceutical Executive
Tezepelumab is a potential first-in-class human monoclonal antibody that works differently than other biologics by inhibiting the action of ...
#54. S139 Efficacy of tezepelumab in patients with low and high ...
Introduction and Objectives In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced annualized asthma exacerbation rates (AAER) by up to 71% versus ...
#55. Tezepelumab Significantly Reduced Asthma Exacerbations ...
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital ...
#56. Unmet need in severe, uncontrolled asthma: can anti-TSLP ...
PATHWAY study (NCT02054130), tezepelumab reduced asthma exacerbations by up to 71% compared with placebo in patients with severe, uncontrolled asthma across ...
#57. New tezepelumab data shows improvements for severe ...
AstraZeneca and Amgen's thymic stromal lymphopoietin (TSLP) blocker tezepelumab has demonstrated new improvements for patients with severe ...
#58. Tezepelumab prepares to enter the asthma antibody fray
Tezepelumab did not reduce the daily use of oral corticosteroid in the phase III SOURCE trial, the partners reported in December. But, a month ...
#59. AAAAI 2021: Tezepelumab Effective for Uncontrolled Asthma ...
February 27, 2021—Tezepelumab can reduce exacerbations, regardless of the initial blood eosinophil count, in patients with severe and ...
#60. Tezepelumab - KEGG DRUG
Tezepelumab (genetical recombination) (JAN). Formula. C6400H9844N1732O1992S52. Exact mass. 144498.7714. Mol weight. 144588.4306. Sequence. (Heavy chain)
#61. Amgen/AstraZeneca - Tezepelumab - AdisInsight
Tezepelumab is a fully human monoclonal antibody, being developed by Amgen and AstraZeneca, for the treatment of asthma, chronic obstructive pulmonary ...
#62. AstraZeneca and Amgen quietly admit tezepelumab setback ...
AstraZeneca and Amgen have blockbuster ambitions for their tezepelumab antibody, aiming to challenge the Regeneron and Sanofi giant Dupixent ...
#63. FDA Awards AstraZeneca and Amgen's Tezepelumab ...
The FDA granted breakthrough designation for AstraZeneca and partner Amgen's severe asthma treatment, tezepelumab, marking AstraZeneca's ...
#64. Tezepelumab reduced annual exacerbation rates in patients ...
1. Subcutaneous tezepelumab treatment was shown to reduce the rate of annual asthma exacerbations in patients with severe asthma compared to ...
#65. New Tezepelumab Data Show 86% Reduction In ...
New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps.
#66. FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN ...
FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA First and Only Biologic to Consistently and Significantly Reduce ...
#67. Biologic Tezepelumab Reduced Eosinophil Counts in ...
Tezepelumab is a novel human monoclonal antibody that targets the cytokine thymic stromal lymphopoietin (TSLP), which is a key driver of airway ...
#68. Therapeutic: tezepelumab for asthma - Manufacturing Chemist
Tezepelumab acts via a new mechanism: it targets and blocks thymic stromal lymphopoietin (TSLP). 1. This epithelial cytokine is at the top of ...
#69. Tezepelumab Reduces Exacerbations in Severe ...
New data from a phase 3 clinical trial demonstrated promising results for tezepelumab in adults and adolescents with severe asthma.
#70. tezepelumab Archives - The Antibody Society
Tezepelumab (AMG157, MEDI-9929) is a human IgG2 antibody that targets a cytokine, thymic stromal lymphopoietin, that plays a key role in asthma inflammation.
#71. NEJM on Twitter: "Tezepelumab is a monoclonal antibody that ...
Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin. This randomized, placebo-controlled clinical trial showed a reduction in the ...
#72. Tezspire (tezepelumab) approved in the US for severe asthma
AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and paediatric ...
#73. Tezepelumab Overview - Creative Biolabs
Tezepelumab (formerly MEDI9929 and AMG 157) is a human monoclonal antibody (mAb) developed in collaboration by MedImmune (now part of AstraZeneca) and Amgen. It ...
#74. Amgen Submits Biologics License Application for ...
Tezepelumab is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients.
#75. Phase III Results Put Novel Asthma Biologic on Target for ...
Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), cut the annualized rate of asthma exacerbations by more ...
#76. Tezepelumab potential for noneosinopilic asthma backed by ...
AstraZeneca/Amgen's endeavor with tezepelumab in severe asthma could encompass the hitherto unaddressed noneosinophilic patient subgroup.
#77. Tezepelumab Pharmacokinetics, Safety, and Tolerability After ...
Tezepelumab is in development for the treatment of asthma and chronic obstructive pulmonary disease. In the largest study of tezepelumab to date ...
#78. Tezepelumab
Tezepelumab (INN; development codes MEDI9929 and AMG 157) is a human monoclonal antibody designed for the treatment of asthma and atopic dermatitis.
#79. Tezepelumab significantly reduces exacerbations of severe ...
In a Phase III trial, tezepelumab meaningfully reduced annualised asthma exacerbation rates in patients with severe, uncontrolled asthma.
#80. Tezepelumab May Improve Peak Expiratory Flow in Patients ...
In a secondary analysis of the phase 3 NAVIGATOR clinical trial, the novel thymic stromal lymphopoietin inhibitor tezepelumab was shown to ...
#81. Tezepelumab – Medicines – SPS - Specialist Pharmacy Service
May 21 · Amgen submit BLA for tezepelumab to FDA for treatment of patients with severe, uncontrolled asthma [16]. Dec 20 · Filings planned for ...
#82. Tezepelumab, an anti-thymic stromal lymphopoietin ...
Tezepelumab (AMG 157/MEDI9929) is a first-in- class, fully human immunoglobulin G2l monoclonal antibody that specifically binds TSLP and.
#83. API | tezepelumab - Clinical Drug Experience Knowledgebase
API Milestones All Trials. Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma.
#84. Tezepelumab: a novel biological therapy for the treatment of ...
Introduction: Thymic stromal lymphopoietin (TSLP) is overexpressed in the airways of severe asthmatics and is an upstream cytokine that orchestrates ...
#85. Source flop raises tezepelumab questions | Evaluate
But a pivotal failure for Astrazeneca and Amgen's big asthma hope tezepelumab, not long after a previous phase III success, raises questions ...
#86. AstraZeneca shares boosted by Tezepelumab win in severe ...
"Tezepelumab works differently from any other asthma biologic medicine and targets multiple inflammatory pathways that contribute to asthma ...
#87. Tezepelumab - DocCheck Flexikon
Tezepelumab ist ein humaner monoklonaler Antikörper gegen das Zytokin TSLP (thymic stromal lymphopoietin) u.a. zur Behandlung von Asthma ...
#88. Research roundup: Tezepelumab in adults with uncontrolled ...
Research roundup: Tezepelumab in adults with uncontrolled asthma. Author Dr Gareth Hynes, clinical research fellow in severe asthma, ...
#89. EMEA-001613-PIP01-14-M04 | European Medicines Agency
Active substance. tezepelumab ; Therapeutic area. Pneumology-allergology ; Decision number. P/0012/2020 ; PIP number. EMEA-001613-PIP01-14-M04.
#90. Tezepelumab monoclonal antibody drug. Targets thymic ...
Download this stock image: Tezepelumab monoclonal antibody drug. Targets thymic stromal lymphopoietin (TSLP). Generic name and stylized antibody ...
#91. A Complex Trap: Potential new therapeutics for Asthma ...
Figure 2: Novel TSLP cytokine traps and Tezepelumab are potent antagonists ... structure for monoclonal antibody Tezepelumab (AMG-157)AMG-157Fab fragment, ...
#92. Tezepelumab Reduces Multiple Key Inflammatory Biomarkers ...
A2677 - Tezepelumab Reduces Multiple Key Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma in the Phase 2b PATHWAY Study. Presenter:.
#93. III期SOURCE研究受挫,Tezepelumab仍被看好- MP頭條
跌宕: Tezepelumab SOURCE研究未達主要終點2020年11月10日,安進/阿斯利康聯合宣布其TSLP抗體Tezepelumab治療重度哮喘的三期臨床NAVIGATOR獲得成功; 儘管後續SOURCE ...
#94. TEZSPIRE (tezepelumab) Approved in the US for ... - YouTube
#95. III期SOURCE研究受挫,Tezepelumab仍被看好 - 知乎专栏
跌宕:Tezepelumab SOURCE研究未达主要终点2020年11月10日,安进/阿斯利康联合宣布其TSLP抗体Tezepelumab治疗重度哮喘的三期临床NAVIGATOR获得成功; ...
tezepelumab 在 Tezepelumab in... - The New England Journal of Medicine 的推薦與評價
Tezepelumab in Patients with Severe, Uncontrolled Asthma - Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin, ... ... <看更多>